肌肉萎縮症治療市場：依療法、疾病、最終用戶和地區分類

Muscular Dystrophy Treatment Market, By Treatment Type, By Disease Type, By End User, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，肌肉萎縮症治療市場規模將達到 52.2 億美元，到 2033 年將達到 108.3 億美元。預計從 2026 年到 2033 年，該市場將以 11.0% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	52.2億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.00%	2033年市場規模預測：	108.3億美元

全球肌肉萎縮症治療市場涵蓋多種治療類別，包括基因療法、外顯子跳躍療法和皮質類固醇，用於治療Duchenne氏肌肉失養症、貝克氏肌肉萎縮症和肢帶型肌肉萎縮症。市場需求主要源自於對更有效率、更可靠解決方案的需求，以及醫院和專科診所對這些療法的日益普及。技術的不斷進步和終端用戶需求的持續成長正在推動該市場的發展。

市場動態：

Duchenne氏肌肉失養症貝克氏肌肉萎縮症治療方案的日益普及、終端用戶需求的成長以及對提高治療效率和療效的持續關注，預計將成為全球肌肉萎縮症治療市場成長的主要驅動力。更多樣化的選擇也使得這些解決方案能夠惠及更廣泛的使用者群體。

例如，各公司正在拓展產品系列，以滿足醫院和專科診所不斷變化的需求。此外，預計在預測期內，加大對創新和新技術整合的投資，將為市場參與者創造新的成長機會。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，對全球肌肉萎縮症治療市場的主要參與者進行了概況介紹。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球肌肉萎縮症治療市場」報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業利益相關相關人員。
相關人員可以利用全球肌肉萎縮症治療市場分析中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家

第8章競爭情勢

Sarepta Therapeutics
PTC Therapeutics
BioMarin Pharmaceutical
Roche Holding AG
Pfizer Inc.
Novartis AG
Catalent Inc.
Solid Biosciences
Audentes Therapeutics（Astellas Pharma subsidiary）
Summit Therapeutics

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI914

Muscular Dystrophy Treatment Market is estimated to be valued at USD 5.22 billion in 2026 and is expected to reach USD 10.83 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5.22 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.00%	2033 Value Projection:	USD 10.83 billion

The global muscular dystrophy treatment market covers a broad set of treatment type categories, including Gene Therapy, Exon-Skipping Therapeutics, and Corticosteroids, used across applications such as Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Limb-Girdle Muscular Dystrophy. Demand is supported by adoption among Hospitals, and Specialty Clinics and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Duchenne Muscular Dystrophy, and Becker Muscular Dystrophy, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global muscular dystrophy treatment market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Hospitals, and Specialty Clinics. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Sarepta Therapeutics, PTC Therapeutics, BioMarin Pharmaceutical, Roche Holding AG, Pfizer Inc., Novartis AG, Catalent Inc., Solid Biosciences, Audentes Therapeutics (Astellas Pharma subsidiary), and Summit Therapeutics, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscular dystrophy treatment market.

Detailed Segmentation:

Global Muscular Dystrophy Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
Gene Therapy
Exon-Skipping Therapeutics
Corticosteroids
Anti-inflammatory Drugs
Others
Global Muscular Dystrophy Treatment Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Limb-Girdle Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Others
Global Muscular Dystrophy Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Specialty Clinics
Homecare Settings
Research Institutes
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Sarepta Therapeutics*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
PTC Therapeutics
BioMarin Pharmaceutical
Roche Holding AG
Pfizer Inc.
Novartis AG
Catalent Inc.
Solid Biosciences
Audentes Therapeutics (Astellas Pharma subsidiary)
Summit Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Muscular Dystrophy Treatment Market, By Treatment Type, 2026-2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Exon-Skipping Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

5. Muscular Dystrophy Treatment Market, By Disease Type, 2026 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Duchenne Muscular Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Becker Muscular Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Limb-Girdle Muscular Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Facioscapulohumeral Muscular Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

6. Muscular Dystrophy Treatment Market, By End User, 2026 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

7. Muscular Dystrophy Treatment Market, By Region, 2026 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
  - Bahrain
  - Kuwait
  - Oman
  - Qatar
  - Saudi Arabia
  - UAE
  - Israel
  - South Africa
  - North Africa
  - Central Africa
  - Rest of Middle East

8. Competitive Landscape

Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Catalent Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Solid Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Audentes Therapeutics (Astellas Pharma subsidiary)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Summit Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies